#NSCLC

Joshua Bauml, MD

Jbauml

Up next I am going to go through the CodeBreaK100 trial, evaluating AMG510 in patients with KRAS G12C+ NSCLC. I know a lot of people have already gone over these

Joshua Bauml, MD

Jbauml

Tonight at #WCLC20 we saw a RCT presented by Dr Lai on behalf of co-authors looking at immunotherapy in patients with EGFR+ NSCLC. Patients had disease that progressed on at

Joshua Bauml, MD

Jbauml

Next up @JSabari is presenting data on amivantamab in EGFR Exon20ins+ NSCLC. I have participated in the development of amivantamab, though I am not on this particular abstract. Excited to

Stephen V Liu

StephenVLiu

#OncoAlert Retrospective report @JTOonline on outcomes with chemoradiation plus durvalumab (PACIFIC) in patients with #EGFR mutant NSCLC. #LCSM https://www.jto.org/article/S1556-0864(21)01702-0/fulltext Cohort of 37 patients with #EGFR muta

Joshua Bauml, MD

Jbauml

The first abstract I want to talk about is a featured poster I am honored to present on behalf of my coauthors. FP14.06. This was a multicenter effort across North

Ryan Reeves

investing_city

Genomics Thread #6Let's talk about liquid biopsies... 1/ A liquid biopsy is usually a blood-based test that can detect cancer. How?By detecting either CTC (circulating tumor cells) or ctDNA (circulating

Stephen V Liu

StephenVLiu

#OncoAlert Available @NEJM, results from the phase III CROWN trial of lorlatinib versus crizotinib as first line treatment for #ALK NSCLC. Initially presented at virtual #ESMO20, lorlatinib had a significantly

Sandip Patel MD

PatelOncology

KEYNOTE-158 study out in Lancet Oncology, Pembrolizumab for TMB>10- most data time date we have seen since FDA approval, key aspects include tumor types studiedhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30445-9/fu

Bertrand Delsuc

BertrandBio

on STAT3 druggabilityTargeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides (ASOs)https://mct.aacrjournals.org/content/early/2021/01/21/1535-7163.MCT-20-0599 $AZN $IONS danvatirsen data

Chris Jones

CAJonesMD

@DukePallCare SUCCESS! Journal Club Time Machine: Speed Dating with the Classics. Format - everyone in attendance (MS2-Attending) teaches a classic article for 4 minutes, it is put in context by

Amit Kulkarni

AmitKulkarniMD

#FDA recently approved #pembrolizumab- a tissue agnostic indication in metastatic tumors with high #TMB (>10 mut/MB) using Foundation One Dx companion diagnostic test. I want to share a tweetorial on

Lorand Kis

kis_lorand

Spindle cell tumor in the dermis. Any thoughts on what it could be? #pathology #IHCpath #dermpath 1. Thanks everyone for engaging!!! Differential diagnosis includes and is not limited to:Benign lesions/tumors-

Pashtoon Kasi MD, MS

pashtoonkasi

Another agnostic approval.#Pembrolizumab #TMBTMB cutoff >=Though I’m overall very supportive of agnostic approvals overall, not sure if TMB is the same across tissue types. @US_FDA #OncoAlert #PrecisionMedicine https://seekingalpha.com

Shrey Srivastava

BlogShrey

#DDDD $DDDD $LBPS $LOACA very promising RNS today.Bit by bit analysis below. #DDDD $DDDD $LBPS $LOAC'We have generated additional safety and efficacy data, building on the positive data from both

Game Changer Capital (John)

gamechangercap

$NVCR A on why I have been buying since late 2016 and think the SP could go to $500. In 2000 Yoram Palti created a new cancer treatment based on

Rita Faria

RitaINdeFaria

I'm now logging into #ISPOREurope live session IP3: The Meaning of Cure – the Search for What? with @NRLatimer, @BettinaRyll, and K. Jack Ishak and Ágnes Benedict from @evideraglobal https://ispor-europe2020.secure-platform.com/a/gal

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.